FDA approves first drug for postpartum depression
On March 19, the FDA approved Zulresso (brexanolone) injection for intravenous (IV) use for the treatment of postpartum depression. Zulresso will be available only through a restricted program…
Reader Survey
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.
